Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948014 | 0.95 | PTGER4 (0.66) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2939064 | 0.95 | PTGER4 (0.66) | PTGER4CYP1A2CYP2D6THRB | |
| SCHEMBL1591348 | 0.92 | PTGER4 (0.63) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3231068 | 0.92 | PTGER4 (0.63) | PTGER4CYP1A2CYP2D6THRB | |
| SCHEMBL2426297 | 0.92 | PTGER4 (0.63) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2928448 | 0.92 | PTGER4 (0.61) | PTGER4CYP1A2CYP2D6THRB | |
| SCHEMBL13177483 | 0.89 | PTGER4 (0.59) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2936637 | 0.89 | PTGER4 (0.58) | PTGER4CYP1A2CYP2D6THRB | |
| SCHEMBL3965044 | 0.88 | PTGER4 (0.71) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL9947708 | 0.87 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081897-B1 | ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | claimed |
| US-20100076048-A1 | Isoindol Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | claimed |
| EP-2081897-B1 | ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| EP-2081897-B1 | ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-20100076048-A1 | Isoindol Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100076048-A1 | Isoindol Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100076048-A1 | Isoindol Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2008046798-A1 | ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076048-A1 | Isoindol Derivatives As EP4 Receptor Agonists | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CYP1A2 218/4885CYP2D6 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.